Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.5450
-0.0175 (-3.11%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Company Description
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.
Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.
The company was founded in 2019 and is based in Naples, Florida.
Conduit Pharmaceuticals Inc.
Country | United States |
Founded | 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 6 |
CEO | Andrew Regan |
Contact Details
Address: 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 United States | |
Phone | (646)-491-9132 |
Website | conduitpharma.com |
Stock Details
Ticker Symbol | CDT |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001896212 |
CUSIP Number | 20678X106 |
ISIN Number | US20678X1063 |
Employer ID | 87-3272543 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Andrew Regan | Founder, Chief Executive Officer and Director |
James Bligh | Interim Chief Financial Officer and Director |
Dr. David Joszef Tapolczay | Head of Strategy and Licensing |
Dr. Joanne M. Holland | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 25, 2025 | DEF 14A | Other definitive proxy statements |
Apr 25, 2025 | 8-K | Current Report |
Apr 22, 2025 | S-3 | Registration statement under Securities Act of 1933 |
Apr 16, 2025 | PRE 14A | Other preliminary proxy statements |
Apr 16, 2025 | 8-K | Current Report |
Apr 10, 2025 | SCHEDULE 13G/A | Filing |
Apr 4, 2025 | 8-K | Current Report |
Apr 2, 2025 | 8-K/A | [Amend] Current report |
Apr 1, 2025 | 8-K | Current Report |
Mar 28, 2025 | 10-K | Annual Report |